RxDoctor Payments Data

Jesse Schmid, MD

Otolaryngology · Lincoln, NENPI 1407207319

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.8% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Sanofi at 24.1% of the total. Reporting peaked in 2023 at $999 and has fallen 59.0% since, to $410 in 2025.

$2,841in general payments, 2019–2025

Across 105 payments — averaging $27.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$686
  • Regeneron Healthcare Solutions, Inc.$378
  • Stryker$324
  • Cochlear Americas$300
  • AbbVie$185
  • Optinose US, Inc.$177
  • plus $791 from 12 others

What the payments were for

  • Food & beverage$2,60992%
  • Education$2338%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,841 in reported general payments places this provider in the 75th percentile of 86 otolaryngology providers in Nebraska.

See all otolaryngology providers in Nebraska

Medicare billing

Part B allowed, 2024
$157,776
Medicare patients
326
Services billed
1,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Azelastine Hcl186$4,916
Fluticasone Propionate195$3,210
Ipratropium Bromide42$1,294
Ofloxacin68$1,171
Tobramycin-DexamethasoneTobramycin/Dexamethasone11$520
Fluocinonide13$482
Mupirocin51$418
Levocetirizine Dihydrochloride46$294
Ciprofloxacin Hcl13$253
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$233
Tramadol Hcl52$186
Ondansetron Hcl69$125
Prednisone23$55

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →